small molecule

STAVUDINE

STAVUDINE

Loss of exclusivityloss of exclusivity
CompanyCiplaSee this company's full patent-cliff portfolio

Drug detail

Brand nameSTAVUDINE
Active ingredientSTAVUDINE
Strength1MG/ML
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2009
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

STAVUDINE patent cliff — loss of exclusivity — | CliffBio